dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Zionexa completes a second $5 million capital raise

SNMMI and ACR collaborate on clinical data registry for nuclear medicine

New PET imaging biomarker could better predict progression of Alzheimer's disease

MILabs installs new E-Class SPECT/CT system to enhance heart failure research at CHFC in Germany

Nordion and BRIT collaborate to bring cobalt-60 from India to global markets

Bruce Power completes harvest of Cobalt-60 that will save lives through cancer treatments

Nordion and Tong Xing expand cobalt-60 supply agreement

Advanced imaging technology predicts cardiovascular risk from inflammation detected in arteries

TRIUMF receives historic investment in 2019 federal budget

DOSIsoft PLANET Onco Dose receives FDA clearance for molecular imaging & molecular radiotherapy dosimetry

Enigma Biomedical Group signs license agreement with Merck for novel MK-6884 imaging agent

Press releases may be edited for formatting or style
TORONTO--(BUSINESS WIRE)--Enigma Biomedical Group (EBG) today announced an exclusive license agreement with Merck, known as MSD outside the US and Canada, for the global development and commercialization of MK-6884, an early stage investigational imaging agent developed by Merck for use in Positron Emission Tomography (PET) scans to measure cholinergic tone change in vivo. MK-6884 has potential applications as an imaging agent across multiple neurodegenerative diseases.

As part of the agreement, EBG will be responsible for the clinical development and commercialization of MK-6884 in return for payment of license fees, milestone payments and royalties on worldwide sales of any future marketed products.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



Lee Ann Gibbs, President of Enigma Biomedical Group said, “This is an important step in accelerating critical biomarker research projects globally. Licensing this additional Merck technology allows Enigma, and its partner, Cerveau Technologies Inc., to continue to execute the collective strategy of providing biomarkers to industry and academia to accelerate research in the field of neurodegenerative diseases.”

“There is a critical need to develop imaging agents for the diagnosis and characterization of neurodegenerative diseases,” said Jeff Evelhoch, Vice President, Translational Biomarkers, Merck Research Laboratories. “We are pleased to work with Enigma and Cerveau.”

In an early study presented at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2019 Annual Meeting, Merck scientists reported that cholinergic tone alters M4 Positive Allosteric Modulation (PAM) and PET imaging with [11C]MK-6884 was able to measure cholinergic tone change. MK-6884 has a high specificity with favorable physicochemical properties and in vivo pharmacokinetics that warrant further clinical investigation as a potential PET neuroimaging agent. Merck and Cerveau are planning an open-label Phase 1 study to investigate the safety and characterize the use of [11C]MK-6884.

“At Cerveau, we are focused on providing information and technologies to researchers and clinicians to enable the improvement of brain health,” said Rick Hiatt, President and Chief Executive Officer of Cerveau Technologies, Inc. “We are thrilled by the opportunity to once again work with Merck to foster development of this exciting technology. Consistent with our vision, we will make these novel imaging agents available to our pharmaceutical industry and academic partners, providing access to the broader scientific community.”


About Enigma Biomedical Group
Toronto-based Enigma Biomedical Group (EBG) enhances access to key technologies with a focus on molecular imaging and medicine. EBG offers a suite of services to the pharmaceutical industry and clinical research community to accelerate drug development and global access. EBG partners with academic institutions and universities to foster and broaden access to novel research.


About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED